HIV pre-exposure prophylaxis (PrEP) is a prevention strategy which includes the regular or event-driven use of antiretroviral medication to prevent HIV infection in adults. Several clinical trials ...
The guideline is published on World AIDS Day, December 1, 2025, to raise awareness of new approaches to prevention. Pre-exposure prophylaxis involves an HIV-negative person starting antiretroviral ...
A recent study published in JAMA Network Open evaluated the cost-effectiveness of monoclonal antibodies (mAbs) as pre-exposure prophylaxis (PrEP) for coronavirus disease 2019 (COVID-19). Study: Health ...
For several years, pre-exposure prophylaxis against HIV (PrEP) has been a major success in preventing new cases. However, individuals on PrEP typically engage in riskier sexual behavior and thus are ...
Nina T. Harawa ([email protected]), University of California Los Angeles, Los Angeles, California. Diane Tan, University of California Los Angeles. Arleen A. Leibowitz, University of California Los ...
The EUA was supported by primary data from the phase 3 PROVENT trial. The Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for Evusheld (tixagevimab co-packaged with ...
Medicaid expansion under the Affordable Care Act (ACA) significantly increased the number of people at risk of HIV diagnosis who were prescribed preexposure prophylaxis (PrEP), a preventative ...
A new HIV antiretroviral shows promise as a long-acting, oral prophylactic agent, according to a new study by Izzat Raheem, Tracy Diamond and colleagues from Merck & Co., Inc., Rahway, NJ, U.S., ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results